A recent study shows that the Glasgow Prognostic Score (GPS), an inflammation-based score, is effective at predicting high-grade and advanced-stage bladder cancer tumors in patients with blood in their urine who require urgent evaluation. The findings were reported in Anticancer Research.
The study comprised 101 consecutive patients who presented with blood in urine. Of those patients, 77 had a bladder tumor and 24 had no pathology. Patients with bacterial infections or other known malignancies were excluded from analysis. Protein and albumin levels were used to calculate GPS, and multivariate logistic regression was used to discern the link between GPS and diagnoses.
According to the results, 67% of patients with high-grade tumors had a GPS of 1 or 2 compared with 13% of patients with low-grade or negative results. Moreover, nearly half (48%) of patients with high muscle-invasive disease showed a GPS of 2 compared with 6% of patients with high-grade muscle-invasive tumors. Overall, the study showed that GPS is a robust predictor of high-grade and advanced-stage bladder cancer.
Reference: Wallace B, Dekalo S, Kabha M, Mintz I, Matzkin H, Mabjeesh NJ. Can we predict a higher risk of urothelial bladder cancer with a simple blood test? Anticancer Res. 2022;42(7):3569-3573. doi:10.21873/anticanres.15843
